medicine Product List and Ranking from 6 Manufacturers, Suppliers and Companies

Tile glaze: production, types, differences *Technical materials available

Free technical materials explaining the glaze of tiles, including production, types, differences, etc.

The 'Tile Glaze: Production, Types, and Differences' is a technical document that explains the production, types, and differences of tile glazes. We provide know-how that only the tile professionals at 'Exys' can understand. [Contents (a partial introduction)] ■ What is glaze? ■ How is it made? ■ What types are available? ■ Differences in the number of glaze applications and surface conditions, etc. *For more details, please refer to the PDF available for download.

Company：エクシィズ
Price：Other

Tile/indoor/outdoor
tile
Interior and exterior tiles
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Treatment Drug for BRAF Mutant Cancer: T21-052

BRAFV600E mutation cancer treatment agent

The BRAFV600E mutation is observed in multiple cancer types and is associated with a poor prognosis compared to other molecular subtypes. In the treatment of BRAF-mutant colorectal cancer patients, molecular targeted therapies have been developed, including combination therapies of BRAF inhibitors with anti-EGFR antibody drugs, as well as a three-drug combination therapy of BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, which were clinically introduced in 2020. However, BRAF-mutant colorectal cancer still has a poor prognosis, and further effective treatment strategies are needed. Therefore, this invention proposes that retinoid receptor (particularly RARα or RXRα) agonists can enhance treatment effects or overcome acquired resistance in combination therapies of BRAF inhibitors with anti-EGFR antibody drugs or BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, potentially serving as an effective treatment strategy for cancers with BRAFV600E, particularly colorectal cancer.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Treatment and Prevention Agents for Chronic Kidney Disease Complications: T22-116

Components found in mammalian milk suppress the progression of kidney disorders, sarcopenia, and anemia.

Chronic kidney disease currently affects about 1 in 8 adults and is said to be a new national disease in Japan. The treatment aims to slow the progression of symptoms, particularly to prevent the progression to end-stage renal failure and the onset of cardiovascular diseases. CKD also has complications such as bone disorders, muscle atrophy (sarcopenia), and anemia, and there are no effective treatments available. This invention relates to the effects of a protein called lactoferrin (Lf) on the progression and complications of chronic kidney disease (CKD). It was found that the administration of Lf has both preventive effects before the onset of CKD and therapeutic effects after its onset in adenine-induced renal failure model mice (Reference 1). Specifically, the effects of Lf in suppressing sarcopenia (reduction of muscle cross-sectional area, decrease in the accumulation of uremic toxins in muscles), anemia, renal atrophy, tubular interstitial damage, decline in renal function, and inflammation and fibrosis in the kidneys were confirmed.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology：Renal function improving agent：T13-090

Drug repositioning of Lubiprostone Exploratory P2 is over!

　Toxin adsorbents such as SGLT2 inhibitors and cremedin have been used as pharmacotherapy for kidney disease. Lubiprostone, which is also used as a constipation drug, was shown to be effective as a treatment for chronic kidney disease (CKD). Lubiprostone was also found to suppress the decline in renal function. In an investigator-initiated clinical trial, the inventors conducted an exploratory study to investigate the efficacy and safety of 8 μg/day and 16 μg/day of lubiprostone in reducing renal function in patients with chronic kidney disease, using a placebo control. (The results can be disclosed under individual contracts.)

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology ：Amyloid‑β–Degrading Enzymes Derived from Habu Snake Venom：T23-051

A Highly Selective Amyloid‑β Degrader as a Seed for Alzheimer’s Disease Therapeutics

Current Alzheimer’s disease therapies provide only limited cognitive benefit, and there is an unmet need for disease‑modifying drugs that directly reduce amyloid‑β (Aβ) accumulation. The inventors identified habu snake (Protobothrops flavoviridis) venom metalloproteinases (SVMPs), evolutionarily related to non‑amyloidogenic APP‑processing ADAM proteases, as potent Aβ‑degrading enzymes. In vitro, an SVMP cocktail cleaved secreted Aβ at the APP α‑cleavage–equivalent site, converted it to non‑toxic p3 fragments, and reduced Aβ levels in culture medium by about 90%. Among these, the flavoridin‑precursor–derived SVMP targets both monomeric and aggregated Aβ and shows higher substrate selectivity than neprilysin with minimal neuropeptide degradation, supporting its potential as a low‑toxicity, disease‑modifying AD drug lead.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Book] Early Diagnosis Techniques for Dementia (No. 1988BOD)

[Technical Specialty Book] ◎ The development concept shifts from "healing" to "delaying"!

Book Title: Early Diagnosis Techniques for Dementia and Development of Progression Inhibitors/Preventive Drugs and Functional Foods －－－－－－－－－－－－－－－－－－－－－－－－－－ ◎ What is the approach to conducting clinical trials that ensures success in linking developed active ingredients to products? ◎ Requirements demanded by the functional labeling system for development and tips for maximizing its use! －－－－－－－－－－－－－－－－－－－－－－－－－－ ■ Table of Contents Chapter 1: Diagnostic Techniques for Early Detection of Dementia and Their High Precision Chapter 2: Latest Research Trends in Biomarkers for Dementia Chapter 3: Practical Approaches to Preventing Clinical Trial Cessation and Evaluating Efficacy Chapter 4: Non-Clinical Trials and Model Animal Creation for Dementia to Avoid Failures in Human Clinical Trials Chapter 5: Domestic and International Market Trends and Measures Surrounding the Dementia Issue in 2025 Chapter 6: Research on Targets Expected to Inhibit Progression and Prevent Dementia, and Mechanisms of Onset Chapter 7: Current Status of Diagnosis and Treatment in Clinical Settings and Clinical Needs Chapter 8: DDS Technology Enabling Passage Through the Blood-Brain Barrier and Its Evaluation Chapter 9: Development of Functional Foods and Health Foods (Supplements) Expected to Inhibit Progression and Prevent Dementia

Company：技術情報協会
Price：10,000 yen-100,000 yen

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Innovative AI drug discovery

What does the fusion of medical big data and AI (artificial intelligence) bring to the field of drug discovery? A detailed explanation of the current state and challenges of innovative drug discovery technologies!

Exploring the potential of AI drug discovery through the initiatives of pharmaceutical companies, starting with large-scale projects!

Company：エヌ・ティー・エス
Price：10,000 yen-100,000 yen

Big Data
Database
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Pharmaceutical Composition for the Prevention or Treatment of Fibrosis: T10-134

Suppress the onset and progression of pulmonary fibrosis!!

Pulmonary fibrosis is a disease in which the lungs become fibrotic, shrink, and lose function, leading to inadequate gas exchange. As pulmonary fibrosis progresses, it ultimately results in respiratory distress and can be fatal. There are currently no effective drugs or treatments established for this disease, and the survival period for affected patients is said to be 2 to 3 years. The inventor of this invention has discovered that stanniocalcin 1 (STC1), a hormone in the body, has an inhibitory effect on the onset and progression of pulmonary fibrosis. STC1 is thought to exhibit anti-fibrotic effects by reducing endoplasmic reticulum stress, which is one of the causes of fibrosis, and the associated production of TGF-β1.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Urinary toxin reducers containing tyrosine　: T16-072

L-metatyrosine and 2-azatyrosine intake decreases blood urea toxicity

Phenyl sulfate(PS) and indoxyl sulfuric(IS) are factor of Diabetic nephropathy(DN). Decreasing PS and IS in blood is important for DN treatment.　　This is PS and IS reducing agent with L-metatyrosine and 2-azatyrosine as active ingredients.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Organ Fibrosis Inhibitor: T13-204

Confirmed the effects of fibrosis and inflammation improvement in a kidney fibrosis model mouse!

When the kidneys are damaged for some reason, it is known that inflammation and fibrosis can occur. As symptoms progress, renal failure can develop, necessitating regular dialysis. Dialysis is a significant burden for patients, and there is a desire for the development of therapeutic drugs that can delay the initiation of dialysis. The inventors of this invention have discovered compounds with anti-inflammatory and anti-fibrotic effects. The group of compounds in this invention is expected to be useful as fibrosis inhibitors.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: 1,3-Dioxolane derivative, D-532: T18-094

Renal functions and tissues in diabetic nephropaty models is improved through D-532 oral administration.

The number of dialysis patients continues to increase, and it is known that applox. 40% of the patients requiring dialysis in Japan were ordinally those with diabetic nephropathy (DN). The treatment for DN is often symptomatic by controling blood sugar and blood pressure, and to date, no effective therapeutic agent for curative treatment has been developed.　　This invention discloses a 1, 3-dioxolane compounds D-532 and the derivertives thereof, which inhibits the function of the glucose-responsive transcription factor ChREBP (Carbohydrate responsive element binding protein), for DN treatment. 　D-532 was found by ordinally constructed high-throughput screening based on ChREBP reporter assay with applox. 7,000 of compound library in Tohoku University (Fig.1). Synthesized analogs and isomers thereof were also tested and showed inhibitory effect against ChREBP function, although D-532 showed the highest activity (Data not shown). 　The expression of ChREBP target genes were suppressed by D-532 administration for DN animal model (Fig.2). Urinary albumin excretion and blood creatinine were also improved in DN animals with D-532 (Fig.3). Further, the disappearance of foot process in glomerulus, which is often observed in DN kidney, was suppressed (Data not shown), suggesting that D-532 may act directly to renal tissue and show the effects above.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Method for Suppressing Tumorigenesis of iPS Cells: T18-512

The potential for bone regeneration technology through the transplantation of cultured bone created from iPS cells has been expanded by statin treatment!

Tumorigenesis at the transplantation site of iPS cells is one of the biggest challenges for the application of iPS cells in regenerative medicine. This invention is a technique that suppresses tumorigenesis, which is a problem when transplanting iPS cells for bone regeneration, by using statin-based drugs. It is expected to significantly advance the realization of bone regenerative medicine using iPS cells by contributing to the resolution of tumorigenesis issues without the need for complicated procedures such as cell sorting.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology：Drugs for Stress urinary incontinence：T16-194

Novel mechanisms targeting luteinizing hormone

　Stress urinary incontinence (SUI) is a disorder that affects young and old people and significantly reduces their quality of life. It has been thought to be caused by a decrease in estrogen, but estrogen replacement therapy has not been sufficiently effective, and there is currently no effective oral treatment that is the first choice, so the development of new therapeutic agents is expected. Because of the poor prognosis of SUI in patients with high serum luteinizing hormone (LH) levels before radical prostatectomy, the inventors considered LH to play an important role in urinary function.　　To test this hypothesis, they found that the gonadotropin-releasing hormone GnRH antagonists degarellirex or cetrorellix suppressed LH and improved urethral pressure in model rats that reproduced the menopausal state by removing the bilateral ovaries and had elevated LH. The results showed that there is a relationship between SUI and elevated LH, and that GnRH antagonists that suppress LH may be novel therapeutic agents.　

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku University Technology: Treatment for Coronavirus Disease: T20-033

A small amount of airway administration of biologically derived proteins reduces the invasion of the novel coronavirus and lung damage.

The development of preventive and early treatment drugs for COVID-19 caused by the novel coronavirus (SARS-CoV-2) is desired. This invention relates to Stanniocalcin-1 (STC1), a substance that suppresses the expression of ACE2 and TMPRSS2 (membrane proteins) required for the cellular entry of SARS-CoV-2. - Efficacy: In mice with bleomycin-induced lung injury, STC1 was administered once via the airway, and the lungs were excised on Day 3 and Day 14 to measure the expression levels of ACE2 and TMPRSS2. The results revealed that STC1 suppresses the expression of ACE2 and TMPRSS2 (Figure 1). Previous studies have shown that STC1 has anti-fibrotic and anti-inflammatory effects (related literature 1). In other words, STC1 can simultaneously suppress the viral intracellular entry, lung injury, and cytokine storm associated with COVID-19. - Safety: STC1 is derived from biological sources, and its administration via the airway can suppress systemic viral dissemination. Additionally, it is expected to have high safety due to its effectiveness even at a low dose of 0.1 mg/kg. This dosage is also a realistic amount when translated to human inhalation therapy.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology：The Treatment and Prevention of Inflammatory Bowel Disease ： T23-033

Anti-inflammatory effect by xCT inhibition or Glutamine synthetase inhibition

　The limited number of drugs available for the treatment of inflammatory bowel disease(IBD) and their severe side effects, including immunosuppression, have led to calls for research into drugs without side effects.　　The inventors focused on the role of xCT, a cystine/glutamate antiporter, in IBD. Their research suggests that xCT inhibitors or glutamine synthetase inhibitors may be therapeutic/preventive agents for inflammatory diseases. [RESULTS] ・Mice with intestinal epithelium-specific xCT deficiency showed anti-inflammatory effects on dextran sulfate sodium(DSS) colitis(Fig.1). ・Glutamine synthetase inhibitor (MSO：Methionine sulfoximine) showed anti-inflammatory effects on DSS colitis(Fig.2).

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology：A novel therapeutic target Vasohibin-2: T18-447_T12-072

For the treatment of refractory cancers including pancreatic cancer

Vasohibin-2 (referred to as VASH2) knockdown significantly reduced metastasis of pancreatic cancer cells (Fig. 1) and prolonged survival period after orthotopic transplantation (Fig.2). The mechanisms of action are;　 (1)VASH2 knockdown reduces cancer cell invasion through suppressing of tubulin carboxypeptidase activity within the cell. (2) VASH2 secreted by cancer cells stimulates tumor angiogenesis, so when VASH2 was knocked down, tumor angiogenesis was prevented. (3) VASH2 regulates the production of inflammatory chemokines and cytokines in cancer cells, which in turn, accelerates the recruitment of MDSC and TAM and prevents the infiltration of cytotoxic T lymphocytes. The inhibition of VASH2 eliminates immune suppression in pancreatic cancer.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology： PPARα agonists that improve cognitive function：T22-091

New drug discovery seeds for psychiatric disorders such as schizophrenia

　Recent large-scale genomic and postmortem brain analyses have indicated that synaptic dysgenesis may be involved in the pathogenesis of schizophrenia, but the detailed mechanisms remain unclear. Drugs mainly blocking dopamine D2 receptors have been used for the treatment of schizophrenia, but they are mainly used for symptomatic treatment and have insufficient effects on negative symptoms and cognitive dysfunction. Therefore, it is desirable to develop new drugs based on new molecular mechanisms.　　The inventors have discovered that the decreased function of the PPARA gene, which encodes the nuclear receptor PPARα, is involved in the pathogenesis of schizophrenia [1]. Since PPARα is a transcription factor that can be activated by its ligand, they considered the possibility that activation of PPARA might lead to the improvement of schizophrenia, and found that fenofibrate, a PPARa agonist, is actually effective in improving synaptic function [2]. In this study, they found that pemafibrate, a PPARa agonist, helps to improve cognitive function at the same time as restoring spine density in mice. The invention could lead to the discovery of novel mechanisms for schizophrenia. Furthermore, since decreased spine density and cognitive decline are similar symptoms in other psychiatric disorders such as Alzheimer's, it could also be a therapeutic agent for these disorders.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Tohoku Univ. Technology ：Lubiprostone, a constipation drug, has a kidney protective effect：T25-005

Improvement of Intestinal Microbiota Improves Mitochondrial Function

Chronic kidney disease (CKD) is a major global health issue without any drugs that improve kidney function. Previous mouse experiments showed that lubiprostone, a constipation drug, reduces uremic toxin accumulation by improving the intestinal environment altered by kidney decline, thus inhibiting kidney damage progression 1. A phase II clinical trial was conducted to test lubiprostone's effects on kidney function in patients. Results revealed dose-dependent suppression of kidney function decline (eGFR) in lubiprostone-treated patients compared to placebo. Further analysis showed lubiprostone improves kidney mitochondrial function by modulating the gut microbiota and increasing spermidine production, which enhances mitochondrial activity and provides kidney protection.

Company：Tohoku Techno Arch Co., Ltd.
Price：Other

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Non-explosive, low-vibration steam pressure crushing agent 'Gunsizer'

Contributes to shortening construction time, enhancing safety, and reducing costs! Usable even in situations where work with explosives is not possible. Suppresses shock waves, taking into consideration nearby houses and structures.

The "Gansizer" is a crushing agent that clears the constraints of vibration and noise related to environmental conservation around work sites, achieving efficient crushing through steam pressure. It crushes brittle materials such as rock formations, stones, and concrete structures instantly in a low-vibration state using the steam pressure generated during the thermal decomposition of the agent. Although the crushing procedure is similar to blasting methods, the use of this crushing agent is not subject to the Explosives Control Law. This product enables safe, speedy, and low-cost crushing operations within the construction period. 【Features】 ■ Instant crushing capability ■ Shortened construction period and cost reduction ■ No need for consumption permit notifications due to being non-explosive ■ No waiting time required like static crushing agents ■ Low vibration due to the absence of shock waves ■ Registered in the Ministry of Land, Infrastructure, Transport and Tourism's New Technology Information System (NETIS) It is being used in recovery and reconstruction work following the Great East Japan Earthquake! (Can also be used underwater) *For more details, please refer to the PDF materials or feel free to contact us.

Company：日本工機高機能品営業部
Price：Other

Safety Supplies
Safety and consumables
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

[Book] Latest Immunology (No. 2121)

Free trial available - Specialized literature: How can we advance preparations for vaccine and treatment development in anticipation of the next pandemic?

Book Title: The Latest Immunology and Its Application Technologies That Drug Discovery Researchers and Academia Researchers Should Know The latest mechanisms of pathogenesis that accelerate the development of new drugs for emerging infectious diseases and immune disorders, and the global trends in research and development. ■ Key Points of This Book 1. The latest immune mechanisms and their applications that drug discovery researchers should know - What are the latest research trends and challenges in new drug development both domestically and internationally? 2. The understanding of immune mechanisms for new infectious diseases has progressed to this point! - What are the latest global trends in elucidating pathogenesis for specific diseases? 3. What are the key molecules involved in the onset/control of autoimmune diseases? - The latest research trends on target molecules that could become promising drug discovery targets! 4. Trends in the development of new modalities for vaccines - mRNA vaccines, recombinant VLP (virus-like particle) vaccines 5. How to connect seeds to drug discovery and clinical trials? - Approaches to bridging research in the fields of infectious diseases and immune disorders 6. Trends in the development of DDS (Drug Delivery Systems) for therapeutic drugs for infectious diseases and immune disorders and the development of administration routes.

Company：技術情報協会
Price：10,000 yen-100,000 yen

others
medicine

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World Diabetes Neuropathy Market Research Report (～2027)

Global Diabetes Neuropathy Market (up to 2027): By Treatment Type, By Disease Type, By Distribution Channel, By Region

The market research report by 360iResearch forecasts that the global diabetic neuropathy market size will grow from $3,110.18 million in 2021 to $3,299.45 million in 2022, and further increase at an average annual rate of 6.26% to reach $4,477.84 million by 2027. This report provides a comprehensive analysis of the global diabetic neuropathy market, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by type of treatment (pharmacotherapy, physical therapy), analysis by type of disease (autonomic neuropathy, focal neuropathy, peripheral neuropathy, proximal neuropathy), analysis by distribution channel (clinics, hospitals, online pharmacies, retail pharmacies), regional analysis (North and South America, the United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, the United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World mRNA Therapeutics Market Research Report (to 2027)

Global mRNA Therapeutics Market (up to 2027): By Type, By Application, By End Use, By Region

The market research report by 360iResearch predicts that the global mRNA therapeutics market size will grow from $21.98 billion in 2021 to $27.25 billion in 2022, and further increase at an average annual rate of 24.23% to reach $80.83 billion by 2027. This report provides a comprehensive analysis of the global mRNA therapeutics market, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by type (preventive vaccines, therapeutics, therapeutic vaccines), analysis by application (infectious diseases, tumors, rare genetic disorders, respiratory diseases), analysis by end-use (hospitals & clinics, research institutions), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World Dental Anesthetic Market Research Report 2022-2031

Global Market for Dental Anesthetics 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

Transparency Market Research's market research report projects that the global dental anesthetics market, which was valued at $705.5 million in 2022, will reach $904.1 million by 2031, growing at an average annual rate of 2.6% during the forecast period. This report focuses on the global market for dental anesthetics and includes sections on introduction, assumptions and research methodology, executive summary, market overview, key insights, analysis by type of anesthesia (local anesthesia, general anesthesia, sedatives), analysis by route of administration (oral, intravenous, others), analysis by end-user (hospitals, dental clinics, others), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and competitive landscape.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Market Research Report on Psoriatic Arthritis Treatment Drugs Worldwide 2022-2031

Global Market for Psoriatic Arthritis Treatments 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research report by Transparency Market Research provides a comprehensive investigation and analysis of the global market for psoriatic arthritis treatments, including sections on introduction, assumptions and research methods, market overview, key insights, analysis by drug class (TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others), analysis by route of administration (oral, non-oral, topical), analysis by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), regional analysis (North America, Latin America, Europe, Middle East/Africa), competitive landscape, and company information.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World mRNA Therapeutics Market Research Report (up to 2027)

Global mRNA Therapeutics Market (up to 2027): By Type, By Application, By End Use, By Region

The market research report by 360iResearch predicts that the global mRNA therapeutics market size will grow from $21.98 billion in 2021 to $27.25 billion in 2022, and further increase at an average annual rate of 24.23% to reach $80.83 billion by 2027. This report provides a comprehensive analysis of the global mRNA therapeutics market, including sections on introduction, research methodology, executive summary, market overview, market insights, analysis by type (preventive vaccines, therapeutics, therapeutic vaccines), analysis by application (infectious diseases, tumors, rare genetic disorders, respiratory diseases), analysis by end-use (hospitals & clinics, research institutions), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World T Cell Immunotherapy Market Research Report (–2027)

Global T Cell Immunotherapy Market (up to 2027): By Mechanism of Action, By Product Class, By Type of Treatment, By Disease, By Region

The market research report by 360iResearch predicts that the global T-cell immunotherapy market size will grow from $4,712.10 million in 2021 to $5,309.89 million in 2022, and further increase at an average annual rate of 12.75% to reach $9,684.58 million by 2027. This report provides a comprehensive analysis of the global T-cell immunotherapy market, including an introduction, research methodology, executive summary, market overview, market insights, analysis by mechanism of action (active immunotherapy, passive immunotherapy), analysis by product class (bispecific antibodies, cytokines, monoclonal antibodies, oncolytic virus therapy), analysis by type of treatment (CAR-T, TCR, TIL), analysis by disease (B-cell malignancies, liver cancer, prostate cancer, renal cell carcinoma), regional analysis (North and South America, United States, Canada, Brazil, Asia-Pacific, Japan, China, India, South Korea, Taiwan, Europe/Middle East/Africa, United Kingdom, Germany, France, Russia, and others), competitive landscape, and company information.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World Pain Management Treatment Market Research Report 2022-2031

Global Market for Pain Management Treatment 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The research report by Transparency Market Research provides a comprehensive investigation and analysis of the global pain management treatment market, including sections on introduction, assumptions and research methods, market overview, key insights, analysis by drug type (anticonvulsants, antidepressants, anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), and others), analysis by disease type (neuropathic pain, fibromyalgia, arthritis, chronic lower back pain), analysis by route of administration (oral, non-oral, and others), analysis by distribution channel (retail pharmacies, online pharmacies, and others), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East/Africa), competitive landscape, and company information.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

World Antiradiation Drug Market Research Report 2022-2031

Global Radiation Protection Drug Market 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The market research report by Transparency Market Research investigates and analyzes the global radioprotective drugs market, organizing content such as the introduction, assumptions and research methods, executive summary, market overview, key insights, analysis by compound (potassium iodide (KI), Prussian blue, diethylenetriamine pentaacetate (DTPA), and others), analysis by application (acute radiation syndrome (ARS), cancer treatment, radiation exposure, and others), analysis by distribution channel (hospital pharmacies, retail pharmacies, and others), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), and competitive landscape.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Market Research Report on Chronic Obstructive Pulmonary Disease (COPD) Treatment Drugs Worldwide

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Drug Market 2022-2031: Industry Analysis, Size, Share, Growth, Trends, Forecast

The market research report by Transparency Market Research examines and analyzes the global market for chronic obstructive pulmonary disease (COPD) treatments, organizing content such as the introduction, assumptions and research methods, executive summary, market overview, key insights, analysis by drug class (combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, and others), analysis by type (chronic bronchitis, emphysema), analysis by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), regional analysis (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), and competitive landscape.

Company：マーケットリサーチセンター
Price：Other

others
medicine

View product details

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

medicine Product List and Ranking from 6 Manufacturers, Suppliers and Companies | IPROS

medicine Manufacturer, Suppliers and Company Rankings

medicine Product ranking